Literature DB >> 32458499

Real-world data in Saudi Arabia: Current situation and challenges for regulatory decision-making.

Fatemah A Alnofal1, Adel A Alrwisan1, Thamir M Alshammari1.   

Abstract

PURPOSE: To present the process of establishing a pharmacoepidemiological database in Saudi Arabia, challenges and models used.
METHODS: The database establishment has started in 2017 by piloting the conversion of electronic health records of one hospital to the Observational Health Data Sciences and Informatics (OHDSI), Observational Medical Outcomes Partnership's Common Data Model (OMOP).
RESULTS: During the pilot phase we have faced several challenges such as limited contribution in providing data by local medical institution due to uncertainty about data governance, diversity of systems used by hospitals, inconsistent coding of medical information, and limited awareness about data structure from participating hospital. The pilot phase was completed in 2019 containing information about patient attributes, medical care, therapies, and other additional services for around 130 000 patients in Saudi Arabia. The majority of patients were below the age of 50 years (89%), and acute respiratory infections were the most frequent diagnosis. The data quality was acceptable and no major anomalies were detected during the conversion.
CONCLUSIONS: We demonstrated a successful creation of a pilot database using OHDSI Common Data Model. Our experience with the pilot database could be extended to other institutions to create a national dataset that could be used to generate real-world evidence.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  Saudi Arabia; database; pharmacoepidemiology; real-world data

Mesh:

Year:  2020        PMID: 32458499     DOI: 10.1002/pds.5025

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  1 in total

1.  COVID-19 Vaccine Surveillance in Saudi Arabia: Opportunities for Real-Time Assessment.

Authors:  Yasser Albogami; Hadeel Alkofide; Adel Alrwisan
Journal:  Saudi Pharm J       Date:  2021-07-16       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.